Name: VERRICA PHARMACEUTICALS INC (VRCA) Stock
Brand: VERRICA PHARMACEUTICALS INC
Rating: 3.5 (3 reviews)

VRCA Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

21 days ago - By: Halper Sadeh LLC

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

24 days ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

24 days ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

3 months ago - By: Benzinga

What to Expect from Verrica Pharmaceuticals's Earnings

6 months ago - By: Benzinga

Earnings Outlook For Verrica Pharmaceuticals

a month ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

a month ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

2 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

2 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

2 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: The Motley Fool

Verrica Posts Profit in Fiscal Q2

3 months ago - By: Zacks Investment Research - Mentions: IGC

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

3 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

3 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

3 months ago - By: Zacks Investment Research - Mentions: SLNO

Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

3 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

4 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

5 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

5 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

6 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

6 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

6 months ago - By: Zacks Investment Research - Mentions: IPSC

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

6 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

6 months ago - By: Verrica Pharmaceuticals Inc. - Mentions: TVTX

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

6 months ago - By: Zacks Investment Research - Mentions: ASRT

Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: Zacks Investment Research - Mentions: FDMT

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

6 months ago - By: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

7 months ago - By: Zacks Investment Research - Mentions: AMRX

Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates

7 months ago - By: Verrica Pharmaceuticals Inc.

VERRICA PHARMACEUTICALS INC (VRCA) Stock News

VRCA Latest News, Press Relases and Analysis

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

What to Expect from Verrica Pharmaceuticals's Earnings

Earnings Outlook For Verrica Pharmaceuticals

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Verrica Posts Profit in Fiscal Q2

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York